Brief: Accuray Incorporated Q4 Revenue USD 127.543 Million Vs. IBES Estimate USD 123.8 Million

Accuray

13/08/2025 21:05

Overview

Accuray fiscal Q4 revenue up 14% yr/yr, beating analyst expectations, per LSEG data

Fiscal 2025 revenue rises 3% to $458.5 mln, net loss at $1.6 mln

Co completes debt refinancing, issues FY26 guidance of $471-485 mln revenue

Outlook

Accuray expects FY26 revenue between $471 mln and $485 mln

Company forecasts FY26 adjusted EBITDA of $31 mln to $35 mln

Accuray cites supply chain and economic conditions as potential challenges

Result Drivers

SERVICE REVENUE GROWTH - Service revenue increased by 4% to $56.8 mln, compared to $54.6 mln in the prior year qtr, contributing positively to the overall performance

PRODUCT REVENUE DECLINE - Product revenue fell by 11% to $70.7 mln, down from $79.7 mln in the prior year qtr

GROSS PROFIT IMPROVEMENT - Gross profit margin improved to 30.6% from 28.6% in the prior year qtr, despite a decline in net revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$127.54 mln
$123.80 mln (4 Analysts)
Q4 EPS
$0.01
Q4 Net Income
$1.12 mln
Q4 Basic EPS
$0.01
Q4 Gross Profit
$38.98 mln
Q4 Income From Operations
$4.23 mln
Q4 Operating Expenses
$34.74 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Accuray Inc is $4.25, about 65.2% above its August 12 closing price of $1.48

Press Release: ID:nPn9znmBFa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)